387 related articles for article (PubMed ID: 1280735)
21. [Effects of phenylephrine on atrial natriuretic factor and the renin-aldosterone axis in normal patients and essential hypertensive patients].
Closas J; Genest J; Larochelle P; Cusson J; Gutkowska J; Hamet P; De Léan A; Thibault G; Cantin M
Arch Mal Coeur Vaiss; 1988 Jun; 81 Spec No():75-8. PubMed ID: 2847676
[TBL] [Abstract][Full Text] [Related]
22. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular, renal and endocrine responses to low doses of atrial natriuretic factor in mild essential hypertension.
Cusson JR; Thibault G; Kuchel O; Hamet P; Cantin M; Larochelle P
J Hum Hypertens; 1989 Apr; 3(2):89-96. PubMed ID: 2547952
[TBL] [Abstract][Full Text] [Related]
24. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man.
Connell JM; Whitworth JA; Davies DL; Lever AF; Richards AM; Fraser R
J Hypertens; 1987 Aug; 5(4):425-33. PubMed ID: 2822795
[TBL] [Abstract][Full Text] [Related]
25. [Hemodynamic and renal effects of synthetic atrial natriuretic factor (alpha-h-ANF) in patients with congestive heart failure].
Fontana F; Guardigli G; Cappelli M; Bernardi P
G Ital Cardiol; 1988 Jul; 18(7):567-77. PubMed ID: 2976692
[TBL] [Abstract][Full Text] [Related]
26. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
27. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.
Burnier M; Ganslmayer M; Perret F; Porchet M; Kosoglou T; Gould A; Nussberger J; Waeber B; Brunner HR
Clin Pharmacol Ther; 1991 Aug; 50(2):181-91. PubMed ID: 1831083
[TBL] [Abstract][Full Text] [Related]
28. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
[TBL] [Abstract][Full Text] [Related]
29. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand.
Kukkonen P; Vuolteenaho O; Ruskoaho H
Endocrinology; 1992 Feb; 130(2):755-65. PubMed ID: 1531129
[TBL] [Abstract][Full Text] [Related]
30. Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients.
Piquard F; Richard R; Charloux A; Doutreleau S; Hannedouche T; Brandenberger G; Geny B
J Appl Physiol (1985); 2002 Aug; 93(2):569-75. PubMed ID: 12133866
[TBL] [Abstract][Full Text] [Related]
31. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF
Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404
[TBL] [Abstract][Full Text] [Related]
32. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
[TBL] [Abstract][Full Text] [Related]
33. Humoral and renal response to acute volume loading in patients with essential hypertension.
Horký K; Srámková J; Gregorová I; Dvoráková J
Exp Clin Endocrinol; 1990 Aug; 95(3):361-8. PubMed ID: 2147141
[TBL] [Abstract][Full Text] [Related]
34. Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men.
Motwani JG; Lang CC; Cramb G; Struthers AD
Hypertension; 1995 Apr; 25(4 Pt 1):637-42. PubMed ID: 7721409
[TBL] [Abstract][Full Text] [Related]
35. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.
Dussaule JC; Grangé JD; Wolf JP; Lecomte JM; Gros C; Schwartz JC; Bodin F; Ardaillou R
J Clin Endocrinol Metab; 1991 Mar; 72(3):653-9. PubMed ID: 1847706
[TBL] [Abstract][Full Text] [Related]
36. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
[TBL] [Abstract][Full Text] [Related]
37. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment.
Lainchbury JG; Richards AM; Nicholls MG; Espiner EA; Yandle TG
J Clin Endocrinol Metab; 1999 Feb; 84(2):723-9. PubMed ID: 10022444
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep.
Charles CJ; Espiner EA; Cameron VA; Richards AM; Yandle TG; Sybertz EJ
Hypertension; 1991 May; 17(5):643-51. PubMed ID: 1850715
[TBL] [Abstract][Full Text] [Related]
39. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels.
Richards AM; Espiner EA; Ikram H; Yandle TG
Hypertension; 1989 Sep; 14(3):261-8. PubMed ID: 2527819
[TBL] [Abstract][Full Text] [Related]
40. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Clin Endocrinol Metab; 1991 Jun; 72(6):1317-22. PubMed ID: 1827451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
